Patents
Literature
11 results about "High-content screening" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
High-content screening (HCS), also known as high-content analysis (HCA) or cellomics, is a method that is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. Hence high content screening is a type of phenotypic screen conducted in cells involving the analysis of whole cells or components of cells with simultaneous readout of several parameters. HCS is related to high-throughput screening (HTS), in which thousands of compounds are tested in parallel for their activity in one or more biological assays, but involves assays of more complex cellular phenotypes as outputs. Phenotypic changes may include increases or decreases in the production of cellular products such as proteins and/or changes in the morphology (visual appearance) of the cell. Hence HCA typically involves automated microscopy and image analysis. Unlike high-content analysis, high-content screening implies a level of throughput which is why the term "screening" differentiates HCS from HCA, which may be high in content but low in throughput.
A method for constructing a human endometrial organoid aging model
ActiveCN120888486Bslow growth rateDecreased proliferation indexArtificial cell constructsCell culture active agentsCell Cycle InhibitionCellular Aging
This invention provides a method for constructing a human endometrial organoid aging model, belonging to the field of biological model technology. Based on human endometrial organoids, this invention utilizes hydrogen peroxide (H2O2) stimulation to induce a human endometrial organoid aging model. This human endometrial organoid aging model clearly exhibits multiple cellular aging phenotypes, including slowed organoid growth rate, decreased cell proliferation index (Ki67), enhanced SA-β-gal activity, upregulated expression of cell cycle inhibitors P16 and P21, and significantly upregulated gene expression levels of aging-associated secretory phenotype (SASP) components. It can provide an effective tool for screening anti-aging drugs for women, high-throughput and high-content screening, personalized treatment strategy development, and mechanistic research.
Owner:ZHEJIANG UNIV
New Uses of Oleylethanolamine
This invention belongs to the field of biomedical technology, specifically disclosing the application of oleylethanolamine in the preparation of drugs for preventing and treating intestinal radiation damage, and a drug for preventing and treating intestinal radiation damage. This invention utilizes a small intestinal organoid model and employs high-content screening technology to screen for oleylethanolamine, which can resist radiation damage to intestinal organoids, promote post-radiation regeneration and repair of organoids, promote stem cell proliferation and regeneration, improve post-irradiation survival rate, and alleviate morphological changes in the intestine caused by radiation damage. When oleylethanolamine is prepared into a drug and administered, it can improve intestinal lesions caused by radiation damage, protect stem cells from post-damage regeneration and repair, restore the self-renewal and differentiation functions of stem cells, enable stem cells to self-renew and replenish new stem cells, and differentiate into different types of epithelial cells to protect villous structures, thereby alleviating intestinal damage symptoms.
Owner:ZHENGZHOU UNIV
Degradation agents based on inhibitor fusion covalent fragments and uses
ActiveCN120842239BOrganic active ingredientsOrganic chemistry methodsUbiquitin-Proteasomal PathwayPharmaceutical Substances
The application discloses a degradation agent based on inhibitor fusion covalent fragments and application, and belongs to the technical field of medicines. Specifically, the degradation agent is obtained by fusing covalent fragments of an inhibitor (+) JQ-1 of BRD4 protein. The degradation agent can target BRD4 protein and degrade BRD4 protein. The degradation activity of the degradation agent is screened through two experiments of high-content screening technology and Western blotting, and the best compound M4 in degradation activity is obtained. The compound M4 can induce significant degradation of BRD4 protein within 6 hours, and presents dose dependence; the mechanism of action is to degrade BRD4 protein through an ubiquitin-proteasome pathway mediated by E3 ubiquitin ligase DCAF11. Cell experiments prove that the compound M4 has a broad-spectrum anticancer ability.
Owner:SHENZHEN UNIV
Variable high-microfluidic cell automatic sheet laying and culture system
PendingCN121825739ABioreactor/fermenter combinationsBiological substance pretreatmentsSystems designData acquisition
The invention discloses a variable high-microfluidic cell automatic sheet laying and culture system. The system comprises an automatic driving module, a micro-fluidic chip module and a living cell culture module which have independent functions and are physically matched with one another. By combining the principles of mechanical automation, micro-nano manufacturing and fluid mechanics and adopting a modular system design, the problem that sample preparation standardization, high-quality data acquisition and long-term culture cannot be achieved at the same time, which puzzles the field of high-content screening for a long time, is successfully solved. The system is particularly suitable for application scenes such as rare cell sample analysis, organoid early development observation and drug toxicity test requiring high-resolution morphological quantification, and has high scientific research value and commercial application prospect.
Owner:SUZHOU INST OF BIOMEDICAL ENG & TECH CHINESE ACADEMY OF SCI
Molecular glue degrader mediated by e3 ubiquitin ligase fbxo22 and applications thereof
The application discloses an E3 ubiquitin ligase FBXO22-mediated molecular glue degrader and application thereof, and relates to the technical field of medicinal chemistry. Based on the principle of targeted protein degradation, a series of E3 ubiquitin ligase FBXO22-mediated molecular glue degraders are designed and synthesized. The structure of the molecular glue degrader is shown in formula I or formula II: wherein R 1 and R 2 at least one contains alkylamine substitution. The application screens the activity of the compound by high-content screening technology and Western blotting technology, confirms that the molecular glue degrader can induce the degradation of bromodomain-containing protein 4 and other proteins in its family by E3 ubiquitin ligase FBXO22, thereby can hinder the relevant downstream pathway signals, has the activity of inducing cancer cell death and anti-fibrosis, and is expected to provide a new drug research direction for the treatment of bromodomain protein-related cancer and fibrosis diseases.
Owner:SHENZHEN UNIV
E3 ubiquitin ligase FBXO22 mediated molecular glue degradation agent and application thereof
The invention discloses an E3 ubiquitin ligase FBXO22 mediated molecular glue degradation agent and application thereof, and relates to the technical field of medicinal chemistry. The invention designs and synthesizes a series of E3 ubiquitin ligase FBXO22 mediated molecular glue degradation agents on the basis of a targeted protein degradation principle. The structure of the molecular glue degradation agent is shown as a formula I or a formula II, and at least one of R1 and R2 contains alkylamine substitution. The activity of a compound is screened through a high content screening technology and a protein immunoblotting technology, and it is confirmed that the molecular glue degradation agent can induce degradation of bromodomain protein 4 and other proteins in the family of the bromodomain protein 4 by using E3 ubiquitin ligase FBXO22, so that related downstream channel signals can be hindered; the compound has cancer cell death induction and anti-fibrosis activity, and is expected to provide a new drug research direction for treatment of bromodomain protein related cancers and fibrosis diseases.
Owner:SHENZHEN UNIV
Fluorescently-labeled stem cell line with hepatic stellate cell activation markers, and use thereof
PCT designated stageWO2025187856A1Non-embryonic pluripotent stem cellsArtificially induced pluripotent cellsPluripotential stem cellHepatic stellate cell activation
The present invention relates to a fluorescently-labeled stem cell line with hepatic stellate cell activation markers, and a method for screening for liver fibrosis-inducing factors or fibrosis-inhibiting factors by using same. A human induced pluripotent stem cell line for screening for liver fibrosis-inducing factors or fibrosis-inhibiting factors, prepared according to the present invention, enables screening for an inducing substance capable of inducing liver fibrosis or a substance capable of inhibiting liver fibrosis in a state in which cells are alive in hepatic stellate cells derived from a pluripotent stem cell line, and thus can be used for imaging-based high-throughput screening (HTS) compound discovery and for discovering liver fibrosis-inducing substances or fibrosis-inhibiting substances by using high-content screening equipment.
Owner:KOREA RES INST OF CHEM TECH
Auto high content screening using artificial intelligence for drug compound development
Methods and systems for machine learning are disclosed for automated high content screening of drug compounds. Functions in one method include, receiving an assay layout; receiving images of a plurality of wells in one or more plates; training binary Al models based on the positive phenotype controls versus negative control to generate probabilities of an input image being the positive control to which the binary Al models were trained; training an all-control Al model based on all of the positive phenotype controls and the negative control to generate a set of probabilities of an input image being one of the positive phenotype controls or the negative control; and generating one or more visual representations of the set of probabilities to evaluate performance of the trained all-control Al model and the binary Al models.
Owner:VIQI INC
Method for constructing human endometrial organ aging model
ActiveCN120888486AArtificial cell constructsCell culture active agentsBiotechnologyCell Cycle Inhibition
The invention provides a construction method of a human endometrial organ aging model, and belongs to the technical field of biological models. On the basis of a human endometrial organ, hydrogen peroxide (H2O2) is utilized to stimulate and induce to obtain the human endometrial organ aging model. The human endometrial organoid senescence model can clearly present various cell senescence phenotypes such as slow down of organoid growth speed, reduction of cell proliferation index (Ki67), enhancement of SA-beta-gal activity, up-regulation of expression of cell cycle inhibition proteins P16 and P21, significant up-regulation of gene expression level of senescence-related secretion phenotype (SASP) components, and the like. And an effective tool can be provided for female anti-aging drug screening, high-throughput and high-content screening, individualized treatment strategy development and mechanism research.
Owner:ZHEJIANG UNIV
Degradation agent based on inhibitor fusion covalent fragment and application
ActiveCN120842239AOrganic active ingredientsOrganic chemistry methodsWestern blotUbiquitin-Proteasomal Pathway
The invention discloses a degradation agent based on inhibitor fusion covalent fragments and application, and belongs to the technical field of medicines. Specifically, the degradation agent is obtained by fusing a BRD4 protein inhibitor (+)-JQ-1 with a covalent fragment. The degradation agent can target the BRD4 protein and degrade the BRD4 protein. Degradation activity screening is carried out on the degradation agent through two experiments of a high content screening technology and western blot, and a compound M4 with the best degradation activity is obtained. The compound M4 can induce significant degradation of the BRD4 protein within 6 hours, and presents dose dependence; the action mechanism is that the BRD4 protein is degraded through an E3 ubiquitin ligase DCAF11 mediated ubiquitin-proteasome pathway. Cell experiments prove that the compound M4 has broad-spectrum anti-cancer capability.
Owner:SHENZHEN UNIV
Detection method for mutagenicity of chemicals
The invention discloses a method for detecting mutagenicity of chemicals, the detection method adopts gene editing tetrahymena for expressing fluorescent protein-PIG-P fusion protein for detection, and a construction method of the gene editing tetrahymena comprises the following steps: S1, designing and constructing a fluorescent protein-PIG-P fusion expression vector; and S2, transduction of the fluorescent protein-PG-P fusion expression vector obtained in the step S1 into tetrahymena. The detection method is based on gene editing tetrahymena for expressing PIGP / mCherry on the cell surface, and after the gene editing tetrahymena is exposed to mutagenic chemicals, the intensity of red fluorescence on the cell membrane surface is weakened; in combination with a flow cytometry or a high-content screening system, the detection method provided by the invention can realize rapid, high-throughput and automatic scanning and image analysis, and can be widely applied to rapid detection of mutagenicity of chemicals such as industrial raw material chemicals, small molecule chemicals and pesticides.
Owner:CHINA ACAD OF INSPECTION & QUARANTINE GUANGDONG-HONG KONG-MACAO GREATER BAY AREA RES INST